PERTH, AU, Dec 12, 2019 - (ACN Newswire) - Holista CollTech
(ASX: HCT, Holista) today announced that it has filed its
100%-owned global patent for platform technology that will deliver
many fat-soluble medications by creating a water-soluble delivery
system. This patented process can apply to a whole range of
molecules including the Cannabidiol (CBD) oil industry.
The commercial benefits for the CBD producers include making their
CBD formulation up to 40 times more potent (allowing them to reduce
their dosages significantly) as well as making their product
palatable for the young and the elderly.
Fat-soluble molecules have poor bioavailability as they don't
dissolve well and reach the bloodstream. As such, a higher dosage
needs to be ingested. This is both wasteful and costly. The
platform technology will particularly benefit the Cannabidiol (CBD)
oil industry where the active material is scarce, costly and poorly
water-soluble.
In a statement released this week, by our Project Leader and head
of Holista's Technical Advisory Panel, Dr Roscoe Moore Jr stated
"Working on developing this technology is exciting. Most medicine
consumed orally is wasted due to its poor absorption by the body.
This is especially true for CBD, which is also expensive. More
important, the integrity of the final molecule is preserved exactly
as it is found in nature and hence, there is no apparent need for
any lengthy approvals process anywhere in the world. We only use
materials certified as 'Generally Regarded as Safe' (GRAS) by the
FDA[1]."
Dr Moore is the retired Assistant Surgeon General of the United
States. He currently sits on several Company boards linked to CBD
in the United States and Canada.
CBD Oil has an earthy, musky and lingering bitter taste due to the
high concentration of organic compounds that make it very
unpalatable. This makes formulating CBD for oral consumption
difficult. The taste masking technology linked to this patented
formulation used GRAS botanicals to allow wider applications in
pharmaceutical and food with oral dosing.
"Holista drew from parallel work done on the turmeric molecule
which is also very fat soluble" said Dr Swanand Malode, leader the
teams in Europe and Asia that worked on this technology for more
than five years.
"We note that there is growing consensus in the medical community
that CBD can be used to improve patient outcomes for conditions
such as seizure, inflammation, pain, psychosis or mental disorders,
inflammatory bowel disease, nausea, migraines, depression, anxiety"
said Dr Rajen Manicka, CEO of Holista.
Holista is focused on fat-soluble substances such as CBD, curcumin
and Vitamin D, targeting initially the food and nutraceutical
markets in Australia and North America.
According to a new estimate from cannabis industry analysts the
Brightfield Group[2], the hemp-CBD market alone could hit $22
billion by 2022. The prospects for Australia are also increasing.
According to a 2016 University of Sydney report[3], "Medicinal
Cannabis in Australia: Science, Regulation & Industry", found
that the Australian medicinal cannabis market, if it emulates
cannabis regulations in Netherlands and Canada, may produce demand
for as much as 8,000 kg of product. Australia approved medical
cannabis in 2016 and is working towards liberalising this space
further.
CBD, a non-psychoactive cannabinoid found in cannabis, has had a
surge in popularity. Unlike Tetrahydrocannabinol (THC) the chemical
compound that gives cannabis its psychoactive effects, CBD has been
shown to help patients with Post Traumatic Stress Disorder (PTSD),
anxiety, Multiple Sclerosis and epilepsy - without having the
harmful effects.
The patent was registered in the USA and filed for a global
coverage, as US Filing No: 16/694,197 (the patent may be viewed on
the Holista website). Holista has instructed its patenting firm to
secure all global strategic markets world-wide.
With the patent filing completed, Holista has commenced
negotiations with companies involved in CBD processing in North
America and expect these negotiations to complete in 2020,
leveraging the expertise and network of Dr Moore Jr.
The commercial model will seek to charge an industry-standard
formulation fee for non-exclusive access and then a quarterly
licensing fee and royalty based on wholesale pricing of the
licensee product.
[1] FDA - Food and Drug Administration, USA
[2] For more information on the Brightfield Group, refer to
www.brightfieldgroup.com
[3] Details of the study can be found at
mgcpharma.com.au/wp-content/uploads/2016/03/mgc_whitepaper_final-sml.pdf
For further information, please contact:
Corporate Affairs & Business Opportunities
Dr Rajen Manicka: rajen.m@holistaco.com
General Enquiries: enquiries@holistaco.com
Australia
283 Rokeby Road
Subiaco WA 6008
P: +61 8 6141 3500 ; F: +61 8 6141 3599
Malaysia
12th Floor, Amcorp Trade Centre, PJ Tower
No. 18, Persiaran Barat off Jalan Timur
46000, Petaling Jaya, Malaysia
P: +603 7965 2828 ; F: +603 7965 2777
Media and Investor Relations Enquiries
WeR1 Consultants Pte Ltd
3 Phillip Street #12-01
Singapore 048693
E: holista@wer1.net; P: +65 67374844
About Holista CollTech Ltd (Holista)
Holista is a research-driven biotech company, the result of a
merger between Holista Biotech Sdn Bhd and CollTech Australia Ltd.
Headquartered in Perth and with extensive operations in Malaysia,
the company is dedicated to delivering first-class natural
ingredients and wellness products globally. Holista is a leader in
the research of herbs and ingredients for the making of healthier
food.
Listed on the Australian Securities Exchange (ASX), Holista
researches, develops, manufactures and markets "health-style"
products to address the unmet and evolving needs of natural
medicine. Holista's suite of ingredients, among other things,
includes low-GI baked products, reduced-sodium salts, low-fat fried
foods and low calories sugar without compromising taste, odour and
mouthfeel. Holista remains the only company to produce sheep
(ovine) collagen using patented extraction methods. For more
information, please refer to http://www.holistaco.com
Source: Holista CollTech Ltd
Copyright 2019 ACN Newswire . All rights reserved. |